FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors



Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12015000410501/01/15Novel composition
22014037848712/25/14Tricyclic compounds, preparation methods, and their uses
32014037126412/18/14Muscarinic acetylcholine receptor antagonists
42014033508311/13/14Methods of treatment and prevention of eye diseases
52014031197710/23/14Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
62014028813309/25/143 -amino- pyrazole derivatives useful against tuberculosis
72014022725908/14/14Modified proteins and peptides
82014022726408/14/14Drug fusions and conjugates with extended half life
92014020560407/24/14Antigen binding constructs
102014020566107/24/14Formulation for retinoid-containing soft gelatin capsules
112014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
122014019340707/10/14Drug fusions and conjugates
132014018775007/03/14Methods for selecting protease resistant polypeptides
142014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
152014015870406/12/14Medicament dispenser
162014014099605/22/14Anti-serum albumin biding variable domains
172014011643405/01/14Dry powder inhaler compositions
182014011292904/24/14Tumour necrosis factor receptor 1 antagonists
192014011388804/24/14Novel combination of therapeutic agents
202014011392204/24/14Compounds
212014010589404/17/14Humanized anti-il-18 antibodies
222014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
232014007631403/20/14Manifold for use in medicament dispenser
242014008086303/20/14Muscarinic acetylcholine receptor antagonists
252014005690002/27/14Method for inhibiting binding to b-cell receptor
262014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
272014005071902/20/14Antibodies
282014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
292014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
302014002359601/23/14Novel composition
312014002455801/23/14Method of treatment
322014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
332014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
342013034546512/26/13Process for the preparation of retigabine
352013033698912/19/13Methods of identifying a patient population
362013031590111/28/13Novel uses
372013031704111/28/13Compounds
382013031028111/21/13Novel antigen binding proteins
392013030233511/14/13Ligands that bind tgf-beta receptor ii
402013026771710/10/13Process for the preparation of atovaquone
412013026118510/03/13Benzamide derivatives as ep4 receptor agonists
422013025172409/26/13Antigen binding proteins to oncostatin m (osm)
432013025318809/26/13Novel compounds
442013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
452013022420408/29/13Method of treatment based on atad2 inhibitors
462013021315408/22/13Method of determining cleanliness
472013021339408/22/13Dispensing device
482013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
492013021089208/15/13Method of treatment
502013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
512013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
522013019641208/01/13Magi polynucleotides, polypetides, and antibodies
532013018925507/25/13Fusions and conjugates of insulinotropic agents
542013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
552013011813205/16/13Machine and pharmaceutical and pharmaceutical-like product assembly
562013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
572013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
582013007819803/28/13Novel use
592013005337502/28/13Amino-quinolines as kinase inhibitors
602013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
612013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
622013003001201/31/13Compounds
632013003001501/31/13Muscarinic acetylcholine receptor antagonists
642013002354101/24/13Voltage-gated sodium channel blockers
652013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
662012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
672012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
682012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
692012028854411/15/12Novel retigabine composition
702012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
712012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
722012024074209/27/12Novel device
732012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
742012023855909/20/12Novel compounds
752012023857109/20/12Indazole derivatives as pi 3-kinase
762012023206109/13/12Novel compounds
772012020774908/16/12Dosing regimen
782012020281108/09/12Novel compounds
792012015744606/21/12Medical use
802012015749106/21/12Muscarinic acetylcholine receptor antagonists
812012015749206/21/12Antibiotic drug
822012014971106/14/12Piperidine derivatives used as orexin antagonists
832012014973106/14/12New medical use
842012012868905/24/12Anti-il-23 immunoglobulins
852012012977805/24/12Ligand that bind tgf-beta receptor rii
862012011464705/10/12Anti-serum album single variable domains
872012010013704/26/12Immunoglobulins
882012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
892012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
902012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
912012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
922012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
932012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
942012005896303/08/12Macrolides with anti-inflammatory activity
952012004625802/23/12Novel crystalline pharmaceutical product
962012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
972012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
982012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
992012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1002012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1012012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1022012000632201/12/12Drug dispenser
1032012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1042011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1052011030569212/15/11Antigen-binding contructs
1062011030569312/15/11Anitigen-binding constructs
1072011028809811/24/11Novel compounds
1082011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1092011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1102011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1112011026973811/03/11Compounds
1122011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1132011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1142011025375210/20/11Nozzle for a nasal inhaler
1152011025607410/20/11Novel use
1162011024547010/06/11Immunoglobulins
1172011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1182011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1192011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1202011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1212011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1222011015226206/23/11Novel compounds
1232011014282406/16/11Antibodies against amyloid-beta peptide
1242011014415106/16/11Novel process, salts, composition and use
1252011013569506/09/11Oral dosage form for controlled drug release
1262011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1272011011719005/19/11Pharmaceutical formulations
1282011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1292011006164603/17/11Drug dispenser
1302011006474003/17/11Antigen binding proteins
1312011006572503/17/11Triazole amide derivatives for use in therapy
1322011005916703/10/11Encapsulation of biologically active agents
1332011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1342011004502702/24/11Adjuvant
1352011004613702/24/11Pyrazole derivatives as p2x7 modulators
1362011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1372011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1382011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1392011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1402010032999612/30/10Novel combination of therapeutic agents
1412010032402212/23/10Novel compounds
1422010031657912/16/10Novel use of alkyl phosphate esters
1432010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1442010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1452010030808212/09/10Dispensing device
1462010031170612/09/10Method of treatment of allergic rhinitis
1472010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1482010030382112/02/10Immunoglobulins
1492010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1502010030512712/02/10Novel compounds
1512010030516612/02/10Novel compounds
1522010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1532010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1542010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1552010027590911/04/10Actuator for an inhaler
1562010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1572010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1582010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1592010025619910/07/10Crystalline form of an antimalarial compound
1602010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1612010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1622010022418509/09/10Actuator for an inhaler
1632010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1642010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1652010021683708/26/10Glycine transport inhibitors
1662010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1672010020325608/12/10Method and the application of powder material to substrates
1682010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1692010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1702010019767908/05/10Compounds
1712010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1722010019076407/29/10Novel compounds
1732010018477007/22/10Compounds
1742010018499607/22/10Process of amide formation
1752010017569807/15/10Capsule
1762010017406507/08/10Compounds
1772010014809106/17/10Method and system for rapid phase luminescense spectroscopy analysis
1782010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1792010014401606/10/10Apparatus for the disruption of animal cells
1802010014475506/10/10Novel compounds
1812010014482906/10/10Novel receptor antagonists and their methods of use
1822010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1832010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
1842010013735306/03/10Tricyclic compounds as antibacterials
1852010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
1862010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
1872010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
1882010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
1892010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
1902010011379605/06/10Indole derivatives as s1p1 receptor
1912010010565204/29/10Purines as cysteine protease inhibitors
1922010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
1932010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
1942010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
1952010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
1962010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
1972010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
1982010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
1992010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
2002010006816603/18/10Oral composition comprising dimethicone copolyol
2012010006940903/18/10"novel compounds"
2022010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2032010005905203/11/10Sheet driver for use in a drug dispenser
2042010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2052010005650203/04/10Compounds
2062010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2072010005659503/04/10Pyrazole derivatives as p2x7 modulators
2082010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2092010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2102010002969902/04/10Matrix metalloproteinase inhibitors
2112010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2122010001637101/21/10Indole compounds
2132010001002101/14/10Novel compounds
2142010000052801/07/10Manifold for use in medicament dispenser
2152010000052901/07/10Manifold for use in medicament dispenser
2162010000342001/07/10Medicament dispenser
2172010000423001/07/10Azatricyclic compounds and their use
2182010000424001/07/10Indole compounds
2192009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2202009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2212009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2222009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2232009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2242009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2252009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2262009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2272009029874212/03/09Process for manufacturing lactose
2282009029114611/26/09Process for manufacturing lactose
2292009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2302009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2312009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2322009027035510/29/09Compounds
2332009027051010/29/09Glycine transport inhibitors
2342009025390810/08/09Novel m3 muscarinic acetylchoine receptor antagonists
2352009023644509/24/09Fluid dispenser
2362009023984609/24/09Novel compounds
2372009023284709/17/09Immunogenic compositions
2382009022754709/10/09Novel salt form of a beta2-adrenergic agonist quinolin-2-one derivative
2392009022762909/10/09Compounds having activity at the glycine transporter glyt1 and uses thereof
2402009022157709/03/09Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors
2412009021120108/27/09Apparatus and printing packaging elements
2422009020947208/20/09Amide and peptide derivatives of dialkylenetriamines and their use as transfection agents
2432009020365708/13/09Dual pharmacophores - pde4-muscarinic antagonistics
2442009020367708/13/09Dual pharmacophores - pde4-muscarinic antagonistics
2452009019787108/06/09Dual pharmacophores - pde4-muscarinic antagonistics
2462009019792808/06/09Novel receptor antagonists and their methods of use
2472009018849107/30/09Medicaments
2482009018849207/30/09Canisters for use in metered dose inhalers
2492009019216007/30/09Compounds


ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE